MicroVention, a Terumo subsidiary, today announced its official rebranding to Terumo Neuro, effective immediately.

The company says the name change signifies a new chapter in its evolution while maintaining its commitment to neurovascular care.

Aliso Viejo, California-based Microvention — founded in 1997 and acquired by Terumo in 2006 — develops a number of technologies for supporting neurovascular surgeons in preserving and restoring brain health. As Terumo Neuro, the company expects to continue its legacy of innovation and continue to focus on driving impactful growth.

Carsten Schroeder, president and CEO of MicroVention/Terumo Neuro, said the company plans to expand its strategy beyond a core focus on hemorrhagic and ischemic stroke and access solutions. Schroeder says the company wants to “encompass the neurovascular patient care continuum.”

“This transformation reflects our growth as a company and Terumo’s confidence in our future. For eighteen years, we have maintained independent branding as MicroVention, and now, as Terumo Neuro, we’re combining the best of MicroVention with the full strength and support of the Terumo family,” Schroeder said in a news release. Our culture, speed of innovation, focus on game-changing technologies, and close collaboration with physicians will remain unchanged.”

Recent developments at MicroVention/Terumo Neuro include new product launches and positive study data. In June, the company began the U.S. launch for its LVIS EVO intraluminal support stent. Then, in July, it reported positive one-year study results supporting the use of its WEB 17 occlusion device.